Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
No let-up in Covid-19 vaccine trials
A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.
Sanofi Translates its mRNA interest into big bucks
Sanofi’s $3.2bn move for Translate Bio leaves Arcturus as one of the few affordable independent mRNA players.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
Curevac’s credibility unravels along with its Covid-19 vaccine
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
US appetite for Covid-19 treatments remains undiminished
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
